http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#Head http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#assertion http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#provenance http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#pubinfo http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00073 http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association http://www.w3.org/2000/01/rdf-schema#label rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00073 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#provenance http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#pubinfo http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#sig http://purl.org/nanopub/x/hasSignature YDcxNp4yFb+jd0h70HCt+BBkb4ZchN6ne3J1nCFc4paXBPzEulsalYXCO2GKx+GD6yKlnfFaR3SgWkKm7bfKlYk0SCDkrFxGL1eWvy6a6s500M3YS11pJaOSzKNqhCOdRku30grMgz7kGWG8RlHTmvxP6PWFS90sYDb4y1iHvu0= http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://purl.org/dc/terms/created 2021-07-03T15:24:17.881+02:00 http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs